Literature DB >> 8812537

Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125.

A G Zeimet1, C Marth, F A Offner, P Obrist, M Uhl-Steidl, H Feichtinger, S Stadlmann, G Daxenbichler, O Dapunt.   

Abstract

The aim of the present study was to investigate the extent to which human peritoneal mesothelial cells (HPMCs) are able to participate in the release of tumor marker CA-125 in ovarian cancer and other conditions associated with an involvement of the peritoneum. For this purpose CA-125 shedding was measured in the supernatant culture medium of HPMCs obtained from various donors and seven well-established ovarian cancer cell lines (OVCAR-3, 2780, 2774, SKOV-6, SKOV-8, HOC-7, HTB-77). Furthermore, the influence of inflammatory cytokines [interleukin-1 beta (IL-1 beta), tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFN-gamma)] on CA-125 release in normal and malignant cells was also studied. Constitutive CA-125 shedding was found to be about five times higher in HPMCs as compared with the investigated ovarian cancer cell lines. IL-1 beta and TNF-alpha treatment of HPMCs resulted in a significant reduction in CA-125 release; however, no consistent pattern in CA-125 secretion was found during incubation with either IL-1 beta or TNF-alpha in the various malignant cell lines. IFN-gamma, on the other hand, induced a highly significant increase in CA-125 secretion in ovarian cancer cells, but did not influence the shedding of CA-125 in HPMCs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8812537     DOI: 10.1006/gyno.1996.0253

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  15 in total

1.  Comparative analysis of CA 125, ferritin, beta-2 microglobulin, lactic dehydrogenase levels in serum and peritoneal fluid in patients with ovarian neoplasia.

Authors:  Umran Kucukgoz Gulec; Semra Paydas; Ahmet Baris Guzel; Selim Buyukkurt; Gulsah Seydaoglu; Mehmet Ali Vardar
Journal:  Med Oncol       Date:  2012-01-25       Impact factor: 3.064

2.  Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1.

Authors:  M V Cronauer; S Stadlmann; H Klocker; B Abendstein; I E Eder; H Rogatsch; A G Zeimet; C Marth; F A Offner
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

3.  Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations.

Authors:  Sharon S Hori; Sanjiv S Gambhir
Journal:  Sci Transl Med       Date:  2011-11-16       Impact factor: 17.956

4.  A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.

Authors:  Thomas C Krivak; Chunqiao Tian; G Scott Rose; Deborah K Armstrong; G Larry Maxwell
Journal:  Gynecol Oncol       Date:  2009-07-12       Impact factor: 5.482

5.  Influence of tumor grade on expression of CA 125 in serum and tissue in patients with serous ovarian carcinoma.

Authors:  Igor But
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

6.  Membrane-type I matrix metalloproteinase-dependent ectodomain shedding of mucin16/ CA-125 on ovarian cancer cells modulates adhesion and invasion of peritoneal mesothelium.

Authors:  Lana Bruney; Kaitlynn C Conley; Natalie M Moss; Yueying Liu; M Sharon Stack
Journal:  Biol Chem       Date:  2014-10       Impact factor: 3.915

Review 7.  Cancer antigen 125 as a biomarker in peritoneal dialysis: mesothelial cell health or death?

Authors:  Harpaul Cheema; Joanne M Bargman
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

8.  Ruptured ovarian endometrioma with an extreme rise in serum CA 125 level - A case report: Ovarian endometrioma with very high CA-125 level.

Authors:  Anju Kumari Rani; Deepa Kapoor
Journal:  Gynecol Oncol Case Rep       Date:  2012-05-19

9.  Endometriosis: A Malignant Fingerprint.

Authors:  Christopher DeAngelo; Megan Burnett Tarasiewicz; Athena Strother; Heather Taggart; Caron Gray; Meaghan Shanahan; Christopher Glowacki; Jimmy Khandalavala; Erin Talaska; Andrea Kinnan; John Joseph Coté; Adrienne Perfilio Edwards; Gina Harper-Harrison; Murray Joseph Casey; Traci-Lynn Hirai; Sarah Schultz; Lynnea Stines; Roma Vora; Dominique Boudreau; Jennifer Burgart; Meredith Shama; Trevor Watson; Lisa Strasheim; Rachel Thompson; Rachel Lawlor; Kayleen Joyce; Claire M Magnuson; Jane Driano; Breanna Elger; Anne Lentino; Margaret Driscoll; Elise Tidwell; Apoorva Sharma; Sarah R Walker; Gretchen Jones; Poonam Sharma; Holly Stessman; Yanyuan Wu; Jay Vadgama; Dana Chase; Lesley Conrad; Srinivasa T Reddy; Robin Farias-Eisner
Journal:  J Cancer Res Ther Oncol       Date:  2020-12-29

10.  Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes.

Authors:  Amelie M Lutz; Juergen K Willmann; Frank V Cochran; Pritha Ray; Sanjiv S Gambhir
Journal:  PLoS Med       Date:  2008-08-19       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.